Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

A new study reveals that bariatric surgery results in significantly greater weight loss compared to popular GLP-1 drugs.

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company (NYSE:LLY) is one of Best Dividend Stocks to Buy for Dependable Dividend Growth. According to Adam ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

Eli Lilly is on something of a tear ... The Indianapolis-based pharma is most famous for its obesity and type 2 diabetes drugs, Zepbound and Mounjaro, and Alzheimer’s medicine Kisunla. But in addition ...

Shares of companies that pay reliable dividends can typically be bought and held forever. These five have paid dividends for ...